Coraline Dubot
Overview
Explore the profile of Coraline Dubot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
2346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azais H, Brochard C, Taly V, Benoit L, Ferron G, Ray-Coquard I, et al.
Gynecol Oncol
. 2024 Dec;
192():145-154.
PMID: 39671779
Objective: To evaluate the prognostic impact of circulating tumor DNA (ctDNA) detection at diagnosis (T0) and its early decrease after one cycle (T1) of neoadjuvant chemotherapy (NACT) in patients with...
2.
Moniot A, Schneider C, Chardin L, Yaniz-Galende E, Genestie C, Etiennot M, et al.
Mol Cancer
. 2024 Aug;
23(1):166.
PMID: 39138571
Background: Ovarian cancer (OC) remains one of the most challenging and deadly malignancies facing women today. While PARP inhibitors (PARPis) have transformed the treatment landscape for women with advanced OC,...
3.
Hagege M, Bringuier M, Martinez-Tapia C, Chouaid C, Helissey C, Brain E, et al.
Age Ageing
. 2024 Feb;
53(2).
PMID: 38346934
Background: Few studies of the under-representation of older adults in cancer clinical trials (CTs) have encompassed the entire pathway from a trial being available in a cancer centre to the...
4.
Tewari K, Colombo N, Monk B, Dubot C, Caceres M, Hasegawa K, et al.
JAMA Oncol
. 2023 Dec;
10(2):185-192.
PMID: 38095881
Importance: The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent,...
5.
Monk B, Colombo N, Tewari K, Dubot C, Caceres M, Hasegawa K, et al.
J Clin Oncol
. 2023 Nov;
41(36):5505-5511.
PMID: 37910822
JCO The phase III, double-blind KEYNOTE-826 trial of pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles plus platinum-based chemotherapy, with or without bevacizumab, showed...
6.
Pautier P, Genestie C, Gladieff L, Kurtz J, Lortholary A, de La Motte Rouge T, et al.
Bull Cancer
. 2023 Aug;
110(6S):6S44-6S50.
PMID: 37573038
French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of advanced cervical cancer The prognosis of cervical cancer remained pejorative until recently, first-line treatment consisting of platinum-based chemotherapy, associated with bevacizumab...
7.
Rodrigues M, Vanoni G, Loap P, Dubot C, Timperi E, Minsat M, et al.
Nat Commun
. 2023 Jun;
14(1):3698.
PMID: 37349318
Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed...
8.
Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, Genestie C, Serra V, Herencia-Ropero A, et al.
Gynecol Oncol
. 2023 Jun;
175:194.
PMID: 37271667
No abstract available.
9.
Kamal M, Lameiras S, Deloger M, Morel A, Vacher S, Lecerf C, et al.
Br J Cancer
. 2023 Apr;
128(9):1790.
PMID: 37055522
No abstract available.
10.
Monk B, Tewari K, Dubot C, Caceres M, Hasegawa K, Shapira-Frommer R, et al.
Lancet Oncol
. 2023 Mar;
24(4):392-402.
PMID: 36878237
Background: In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody pembrolizumab to chemotherapy with or without bevacizumab improved overall survival and progression-free survival (primary endpoints) versus placebo plus...